Kodiak Sciences (KOD) Total Non-Current Liabilities (2017 - 2026)
Kodiak Sciences (KOD) posted Total Non-Current Liabilities of $93.9 million for Q1 2026, little changed on a QoQ basis from $94.1 million in Q4 2025, and up 5.43% year-over-year from $89.1 million in Q1 2025.
Kodiak Sciences (KOD) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Kodiak Sciences' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $93.9 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 5.43% year-over-year to $93.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.9 million (up 5.43% YoY) and the FY2025 annual result came in at $94.1 million, up 10.39% from the prior year.
- Total Non-Current Liabilities was $93.9 million for Q1 2026 at Kodiak Sciences, roughly flat from $94.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $252.7 million in Q1 2022 and bottomed at $85.3 million in Q4 2024.
- A 5-year average of $149.8 million and a median of $94.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 85.12% — and 2024, when it sank 65.33%.
- Kodiak Sciences' Total Non-Current Liabilities stood at $130.5 million in 2022, then retreated by 12.93% to $113.6 million in 2023, then declined by 24.91% to $85.3 million in 2024, then rose by 10.39% to $94.1 million in 2025, then decreased by 0.26% to $93.9 million in 2026.
- Business Quant data shows KOD's Total Non-Current Liabilities at $93.9 million in Q1 2026, $94.1 million in Q4 2025, and $94.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Kodiak Sciences | 2.54 Bn | 2.54 Bn | - | 93.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.91 Mn |
| Dec 31, 2025 | 94.15 Mn |
| Sep 30, 2025 | 94.38 Mn |
| Jun 30, 2025 | 86.44 Mn |
| Mar 31, 2025 | 89.07 Mn |
| Dec 31, 2024 | 85.29 Mn |
| Sep 30, 2024 | 87.30 Mn |
| Jun 30, 2024 | 87.07 Mn |
| Mar 31, 2024 | 93.57 Mn |
| Dec 31, 2023 | 113.59 Mn |
| Sep 30, 2023 | 245.24 Mn |
| Jun 30, 2023 | 251.18 Mn |
| Mar 31, 2023 | 247.75 Mn |
| Dec 31, 2022 | 130.47 Mn |
| Sep 30, 2022 | 244.28 Mn |
| Jun 30, 2022 | 250.79 Mn |
| Mar 31, 2022 | 252.71 Mn |
| Dec 31, 2021 | 240.69 Mn |
| Sep 30, 2021 | 131.96 Mn |
| Jun 30, 2021 | 217.94 Mn |